Isolation and characterization of a monomethioninesulfoxide variant of interferon alpha-2b

被引:29
|
作者
Gitlin, G [1 ]
Tsarbopoulos, A [1 ]
Patel, ST [1 ]
Sydor, W [1 ]
Pramanik, BN [1 ]
Jacobs, S [1 ]
Westreich, L [1 ]
Mittelman, S [1 ]
Bausch, JN [1 ]
机构
[1] SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ 07033
关键词
protein mapping; mass spectrometry; methionine oxidation;
D O I
10.1023/A:1016059902645
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To isolate and characterize a monomethioninesulfoxide variant of the commercially available therapeutic protein interferon alpha-2b. Methods. The methionine (Met)-oxidized variant was isolated by reverse-phase high performance liquid chromatography and characterized by SDS-PAGE, peptide mapping and mass spectrometric analysis of the trypsin/V8-generated peptide fragments. The biological and immunological activities of the isolated variant were also evaluated. Results. The rHuIFN alpha-2b variant was found to contain a Met sulfoxide residue at position ill of the rHuIFN alpha-2b molecule. The far-UV CD spectra showed a slight loss of alpha-helical content and an increase in the beta-sheet contribution. The CD spectra indicate that both chromatographic conditions and Met oxidation contribute to the observed secondary structure changes. Both interferon alpha-2b main component and its methionine-oxidized variant showed different reactivity to monoclonal antibodies employed in immunoassays for the protein. Conclusions. A monomethioninesulfoxide rHuIFN alpha-2b variant was found to be present in the rHuIFN alpha-2b bulk drug substance in solution. The Met(111) residue was identified as Met sulfoxide by comparative tryptic/V8 mapping and mass spectrometric analysis. Nevertheless, the oxidation of the Met(111) residue did not seem to have a detectable effect on the biological activity of the molecule.
引用
收藏
页码:762 / 769
页数:8
相关论文
共 50 条
  • [21] RECOMBINANT ALPHA-2B INTERFERON IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES
    LIM, SH
    DONOHUE, SM
    BOUGHTON, BJ
    BLUT, 1988, 56 (06): : C21 - C21
  • [22] Interferon Alpha-2b Therapy in Chronic Hepatitis Delta
    Keshvari, Maryam
    Alavian, Seyed Moayed
    Sharafi, Heidar
    Karimi, Gharib
    Fesharaki, Mohammad Gholami
    HEPATITIS MONTHLY, 2014, 14 (03)
  • [23] Development of interferon alpha-2b microspheres with constant release
    Li, Zhiping
    Li, Lin
    Liu, Yan
    Zhang, Hui
    Li, Xueru
    Luo, Fang
    Mei, Xingguo
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2011, 410 (1-2) : 48 - 53
  • [24] Bortezomib and interferon alpha-2b in metastatic melanoma.
    Markowitz, Joseph
    Luedke, Eric A.
    Grignol, Valerie P.
    Hade, Erinn
    Paul, Bonnie K.
    Mundy-Bosse, Bethany L.
    Thao-Vi Dao
    Kondalasula, Vidya
    Lesinski, Gregory B.
    Olencki, Thomas
    Kendra, Kari Lynn
    Carson, William Edgar
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] PHARMACOKINETICS OF INTERFERON ALPHA-2B IN HEALTHY-VOLUNTEERS
    RADWANSKI, E
    PERENTESIS, G
    JACOBS, S
    ODEN, E
    AFFRIME, M
    SYMCHOWICZ, S
    ZAMPAGLIONE, N
    JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (05): : 432 - 435
  • [26] INTERFERON ALPHA-2B DEPENDENT RECALCITRANT GENITAL WARTS
    LARSEN, J
    PETERSEN, CS
    KROON, S
    DANISH MEDICAL BULLETIN, 1990, 37 (04): : 374 - 375
  • [27] THE EFFECT OF TOPICAL INTERFERON ALPHA-2B ON ACTINIC KERATOSES
    EDWARDS, L
    LEVINE, N
    SMILES, KA
    JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY, 1990, 16 (05): : 446 - 449
  • [28] ALPHA-2B INTERFERON AS INDUCTION THERAPY IN ESSENTIAL THROMBOCYTHEMIA
    GILES, FJ
    MACHIN, SJ
    GOLDSTONE, AH
    BRITISH JOURNAL OF HAEMATOLOGY, 1988, 69 (01) : 108 - 108
  • [29] Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications
    Wang, YS
    Youngster, S
    Grace, M
    Bausch, J
    Bordens, R
    Wyss, DF
    ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (04) : 547 - 570
  • [30] RECOMBINANT ALPHA-2B INTERFERON (RIFN-ALPHA-2B) IN THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA
    KASPARU, H
    REISNER, R
    BERNHART, M
    FORTELNY, A
    PITTERMANN, E
    KRIEGER, O
    LUTZ, D
    BLUT, 1987, 55 (04): : 284 - 284